An Injectable PC10ARGD/Cu2+/DOX Hydrogel for Combined Chemodynamic and Chemotherapy of Tumors

Jie Yang,Xiao-Jie Wang,Si-Mei Li,Dong-Xue Jiang,Yu-Xin Liu,Yan Huang,Di-Di Dong,Wei Hu,Bo Liu
DOI: https://doi.org/10.1080/09205063.2023.2273118
2024-01-01
Abstract:Nowadays, chemotherapy is a common clinical treatment for cancer, but it still faces many limitations and challenges. Therefore, the combination of chemotherapy and other treatments often enhances the effectiveness of treatments. Herein, an injectable hydrogel of PC(10)ARGD/Cu2+/DOX based on Cu2+, hydrophilic doxorubicin (DOX), and genetically engineered polypeptide PC(10)ARGD was prepared. First, Cu2+ was attached to the histidines in the PC(10)ARGD polypeptide by the coordination reaction to form PC(10)ARGD/Cu2+ hydrogel, then the PC(10)ARGD/Cu2+/DOX hydrogel was prepared by encapsulating the DOX into the PC(10)ARGD/Cu2+ hydrogel. The results of scanning electron microscopy showed that the PC(10)ARGD/Cu2+/DOX hydrogel displayed loose porous morphology. In vitro, reactive oxygen species production results showed that the PC(10)ARGD/Cu2+/DOX hydrogel could continuously produce center dot OH in the presence of H2O2. In vitro MTT results showed that the PC(10)ARGD/Cu2+/DOX hydrogel had a good inhibitory effect on cell activity. Flow cytometry further confirmed the antitumor effect of the PC(10)ARGD/Cu2+/DOX hydrogel. In vivo experiment results showed that the tumor volume of mice treated with the PC(10)ARGD/Cu2+/DOX hydrogel was significantly inhibited compared with control groups, which was due to the combination of chemodynamic and chemotherapy. The results of body weight and blood analysis of mice showed that the PC(10)ARGD/Cu2+/DOX hydrogel possessed good biocompatibility.
What problem does this paper attempt to address?